Specifications from a biotechnology industry perspective.
The emergence of new analytical technology and the production of pharmaceuticals for a global market in a cost-effective manner necessitate the establishment of worldwide specifications that are appropriate for the product and the manufacturing process. This requires a thorough knowledge of the protein and control of the systems that produce it as well as an understanding of the accuracy and precision of the assays used for testing. Harmonization of specifications among the worldwide regulatory authorities is critical for the future development of new pharmaceuticals. A continuing dialogue between industry and regulators to achieve this goal needs to be encouraged and supported.
Garnick
R L
RL
Genentech, Inc., South San Francisco, CA, USA.
D001702:Biopharmaceutics / Q000592:standards*; D001709:Biotechnology / Q000191:economics / Q000592:standards*; D003362:Cost-Benefit Analysis; D017277:Drug Approval; D004340:Drug Contamination; D015195:Drug Design; D004341:Drug Evaluation / Q000592:standards* / Q000639:trends; D004345:Drug Industry / Q000191:economics / Q000379:methods / Q000592:standards*; D007391:International Cooperation; D004364:Pharmaceutical Preparations / Q000592:standards; D011786:Quality Control; D011994:Recombinant Proteins / Q000302:isolation & purification / Q000592:standards; D012015:Reference Standards
D004364:Pharmaceutical Preparations; D011994:Recombinant Proteins